Core Points - Karyopharm Therapeutics Inc. will report its second quarter 2025 financial results on August 11, 2025, at 8:00 a.m. ET [1] - A conference call and audio webcast will be hosted by the management team to discuss the financial results and company updates [1] Company Overview - Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies, particularly oral compounds that address nuclear export dysregulation [3] - The company's lead compound, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications and has received regulatory approvals in various international markets, including Europe and China [3] - Karyopharm has a focused pipeline targeting high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL) [3]

Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies in cancer biology and anemia [4] - The company has an approved product, Roxadustat (爱瑞卓®, EVRENZO™), for treating anemia in chronic kidney disease (CKD) patients in multiple regions including China, Europe, and Japan [4] - FibroGen is evaluating a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. [4] - The company is also developing FG-3246 (FOR46), a first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer [4] Leadership Appointment - Dr. Michael Kauffman has been appointed to the Board of Directors of FibroGen effective June 4, 2025 [1] - Dr. Kauffman is recognized as a biotech industry veteran with extensive experience in drug development, particularly in oncology [2] - His expertise is expected to be invaluable as FibroGen progresses its pipeline and approaches near-term clinical milestones [2] Dr. Michael Kauffman's Background - Dr. Kauffman has approximately 30 years of experience in the life sciences industry, focusing on oncology therapeutic products [3] - He currently serves as CEO and president of Nereid Therapeutics Inc. and is a board member of several other biotech companies [3] - His previous roles include co-founder and CEO of Karyopharm, CMO of Onyx Pharma, and leadership positions at Millennium Pharmaceuticals and Biogen [3] - Dr. Kauffman holds an MD and PhD from Johns Hopkins Medical School and is board certified in Internal Medicine [3]